• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Xeris Biopharma Holdings (XERS) After Record Quarter And Debt Retirement Still Looks Undervalued

    Simply Wall St·10/09/2026 14:38:53
    Listen to the news

    Xeris Biopharma Holdings (XERS) drew fresh attention after reporting a record second quarter, with Recorlev driving revenue and management tightening 2026 guidance while fully retiring its convertible notes.

    That record quarter has arrived alongside strong trading momentum, with a 7 day share price return of 10.16% and a 30 day gain of 20.17%. This has fed into a 38.64% year to date share price return and a very large 3 year total shareholder return, suggesting optimism around Xeris Biopharma Holdings is building rather than fading.

    Compare how Xeris Biopharma Holdings stacks up against other high-momentum healthcare names by reviewing the hand-picked 32 healthcare AI stocks that are also drawing fresh interest from traders.

    After a record quarter, retired convertible debt and a sharp move in Xeris Biopharma Holdings shares, the real puzzle now is whether recent gains already reflect the story or the valuation still leaves meaningful room ahead.

    Most Popular Narrative: 17% Undervalued

    Against the latest close at $10.19, the most followed narrative pegs Xeris Biopharma Holdings at a fair value of $12.29, using a 7.24% discount rate and long range earnings estimates to frame the upside case.

    The impending launch of XP-8121, which utilizes proprietary delivery technology to address a significant unmet need in hypothyroidism, opens the door to a high-value market segment underserved by innovation, potentially driving new revenue streams and long-term margin expansion.

    See why 10 investors see Xeris Biopharma Holdings as 17% undervalued.

    Result: Fair Value of $12.29 (UNDERVALUED)

    Still, the bullish Xeris Biopharma Holdings story could crack if XP-8121 stumbles in Phase 3 or if Recorlev uptake lags behind current analyst enthusiasm.

    Find out about the key risks to this Xeris Biopharma Holdings narrative.

    Another View: What Multiples Say About Xeris Biopharma Holdings

    On the flip side of that fair value story, Xeris Biopharma Holdings trades on a P/S of 5.5x, compared with 4.6x for the wider US Pharmaceuticals group and 2.5x for peers, while our fair ratio sits higher at 6.8x. That mix hints at both pricing risk and room to move if sentiment shifts.

    To see how those sales multiples stack up and where the market could gravitate over time, take a look at the See what the numbers say about this price — find out in our valuation breakdown..

    NasdaqGS:XERS P/S Ratio as at Oct 2026
    NasdaqGS:XERS P/S Ratio as at Oct 2026

    Next Steps

    If this mix of enthusiasm and caution around Xeris Biopharma Holdings feels familiar, do not sit on the sidelines while others form the narrative. Review the data, weigh the upside against the issues, and ground your own view with the 3 key rewards and 1 important warning sign.

    Looking for more investment ideas beyond Xeris Biopharma Holdings?

    Do not stop at one story. Put the same curiosity you have for Xeris Biopharma Holdings to work across a wider watchlist of opportunities right now.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.